Phase 1 Study to Evaluate Safety and Effects of PF-08032562 Alone or with Other Cancer Treatments in Advanced or Metastatic Breast and Colorectal Cancer

What this Trial Is About

Researchers are studying the safety and effects of a medication called PF-08032562 in people with advanced or metastatic breast cancer or colorectal cancer. The study also aims to find the best dose of this medication. Participants in the study may have breast or colorectal cancers that have progressed despite previous treatments or for which no standard therapy is available. This is a phase 1 study focusing on treatment evaluation. Participants will take PF-08032562 by mouth in 28-day cycles. Depending on their specific study group, they may receive PF-08032562 alone or combined with other anti-cancer drugs such as fulvestrant, cetuximab, or a chemotherapy regimen including fluorouracil, oxaliplatin, leucovorin, and bevacizumab. These additional therapies are given by injection or infusion during the treatment cycles. Different doses and schedules of PF-08032562 will be tested in dose escalation and dose expansion parts of the study. During the study, participants will be monitored through blood tests, imaging scans, and assessments of tumor response every 8 to 12 weeks. Researchers will track safety by recording adverse events and laboratory abnormalities from treatment start until 30 days after the last dose or a new therapy begins. They will also measure drug levels in the blood and evaluate tumor control and survival over approximately two years. The total duration of participation may vary depending on treatment response and study completion.

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors